

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



## Consolidated Financial Results for the Nine Months Ended December 31, 2024 [Japanese GAAP]

February 14, 2025

Company name: Menicon Co., Ltd.  
 Listing: Tokyo, Nagoya  
 Securities code: 7780  
 URL: <https://www.menicon.com>  
 Representative: Koji Kawaura President and COO  
 Inquiries: Hideki Koga Senior Executive Officer, Corporate Management, CFO  
 Telephone: +81-52-935-1515  
 Scheduled date to commence dividend payments: -  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated Financial Results for the Nine Months Ended December 31, 2024 (April 1, 2024 to December 31, 2024)

#### (1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended December 31, 2024	91,509	4.7	8,569	13.8	8,198	12.8	5,115	11.8
December 31, 2023	87,401	6.0	7,529	(28.9)	7,269	(30.2)	4,576	(33.3)

(Note) Comprehensive income:     Nine months ended December 31, 2024:     ¥           8,435 million [ 23.6%]  
   Nine months ended December 31, 2023:     ¥           6,823 million [ (14.6)%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2024	67.35	62.12
December 31, 2023	60.16	55.57

#### (2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Millions of yen	Millions of yen	%
December 31, 2024	210,873	88,020	40.5
March 31, 2024	179,812	81,804	44.1

(Reference) Equity:    As of December 31, 2024:           ¥           85,497 million  
                               As of March 31, 2024:                   ¥           79,346 million

#### 2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
Fiscal year ended March 31, 2024	Yen	Yen	Yen	Yen	Yen
	-	0.00	-	25.00	25.00
Fiscal year ending March 31, 2025	-	0.00	-		
Fiscal year ending March 31, 2025 (Forecast)				28.00	28.00

(Note) Revision to the forecast for dividends announced most recently:     None

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2025(April 1, 2024 to March 31, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	122,700	5.6	10,000	11.7	9,500	15.5	7,000	54.2	92.19

(Note) Revision to the financial results forecast announced most recently: None

\* Notes:

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 3 (Company name: Oculus Visioncare (S) Pte. Ltd., Oculus (M) Sdn. Bhd., PT Oculus Indonesia )

Excluded: 1 (Company name: Fuji Contact Co., Ltd. )

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement: None

(4) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares):

December 31, 2024: 76,645,888 shares

March 31, 2024: 76,634,388 shares

2) Number of treasury shares at the end of the period:

December 31, 2024: 757,124 shares

March 31, 2024: 424,833 shares

3) Average number of shares outstanding during the period:

Nine months ended December 31, 2024: 75,945,139 shares

Nine months ended December 31, 2023: 76,072,555 shares

(Note) The Company's shares held by "Employee Stock Ownership Plan (Stock Benefit Trust)" and the "Stock Benefit Trust (Employee Shareholder Association Purchase-Type)" are included in the number of treasury shares at the end of the period and the number of treasury shares to be deducted for the purpose of calculating the average number of shares outstanding during the period.

\* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

\* **Explanation regarding appropriate use of business results forecasts and other special instructions**

- Forecasts regarding future performance presented in this material include the outlook for the future, assumptions on which the plan is based, and projections as of the date of announcement of this material. Actual results may differ from the forecasts presented in this material due to various factors.
- For matters concerning the forecast of business results, please refer to "1. Qualitative Information on Quarterly Financial Results for the Period under Review (3) Consolidated Business Results Forecast and Other Forward-looking Information" on Page 4 of the appendix.

## Table of contents of appendix

1. Qualitative Information on Quarterly Financial Results for the Period under Review .....	2
(1) Business Results .....	2
(2) Financial Position .....	3
(3) Consolidated Business Results Forecast and Other Forward-looking Information .....	4
2. Quarterly Consolidated Financial Statements and Notes.....	5
(1) Quarterly Consolidated Balance Sheets.....	5
(2) Quarterly Consolidated Statements of Income and Comprehensive Income.....	7
Quarterly Consolidated Statements of Income .....	7
(For the nine months ended December 31) .....	7
Quarterly Consolidated Statements of Comprehensive Income .....	8
(For the nine months ended December 31) .....	8
(3) Notes to Quarterly Consolidated Financial Statements .....	9
(Going concern assumption).....	9
(Significant changes in amount of shareholders' equity) .....	9
(Changes in accounting policies).....	9
(Additional information).....	10
(Segment information).....	11
(Notes on consolidated statements of cash flows).....	12

# 1. Qualitative Information on Quarterly Financial Results for the Period under Review

## (1) Business Results

We established the current medium-term management plan, “Vision 2030” and are promoting a “1-DAY Lens Strategy Policy: Aim to be a top global player in 1-DAY Lens with original products and services” and an “Orthokeratology Strategy Policy: Aim to be the leading company in orthokeratology-related (Myopia Control-related) business by creating new value related to myopia control” as growth strategy policies under the slogan “New vision of ‘Miru’ for the world.” In addition, we believe that investing in human capital is essential to advance these strategies, and we continue to strengthen our workforce by raising wages for employees and increasing our workforce.

Performances in each business are as follows.

### [Vision Care Business]

In regard to the “1-Day Lens Strategy,” the global contact lens market is witnessing increased demand for daily disposable contact lenses made of highly safe silicone hydrogel material due to the rising myopic population.

In Japan, we aim to increase the ratio of daily disposable contact lens members in the MELS Plan, while at the same time bolstering sales in Europe and North America by expanding business with major mass retailers. We will also continue to boost our daily disposable contact lens supply capacity to meet growing demand by investing in production facilities at the Kakamigahara Plant and Menicon Singapore Pte. Ltd. and starting up the new factory at Menicon Malaysia Sdn. Bhd.

During the nine months ended December 31, 2024, looking ahead at medium to long-term increase in demand for disposable contact lenses in Southeast Asia we acquired 100% of the shares of three distributors in the region, making them wholly-owned subsidiaries. Furthermore, we entered into a strategic partnership with Nanjing Sigo Network Technology Co., Ltd. headquartered in Nanjing, China, to sell disposable contact lenses in China, with the aim of strengthening sales capabilities for disposable contact lenses, which have been growing in the Chinese market.

Regarding the “Orthokeratology Strategy,” the market for orthokeratology lenses and care products used with orthokeratology lenses is being impacted by economic stagnation, the intensifying competitive environment, and the spread of alternative products in China. Meanwhile, demand is expanding in Japan and other Asian countries and is set to grow further going forward. We will aim to expand sales globally through efforts such as increasing the recognition of lens products in conjunction with care products and developing new sales channels, by leveraging a line-up of multiple orthokeratology lenses, including “α Ortho-K,” which is enjoying strong sales in Japan and the rest of Asia, “Menicon Z Night,” which is experiencing robust sales in Europe and Asia, and “Menicon Bloom Night,” a contact lens with a CE marking certification for myopia control, which is expected to see sales expansion in Europe and elsewhere.

During the nine months ended December 31, 2024, we strengthened sales of orthokeratology-related products in China as we did in the first two quarters by enhancing recognition through supporting sales promotion activities and organizing exhibitions at academic conferences there. In Europe, we began preparing for training and other programs in time for the start of sales activities of orthokeratology-related products by Laboratoires Dencott SA, a French company engaging in fitting services and distribution of contact lenses, which became our wholly-owned subsidiary in March 2024.

### [Other Businesses]

The healthcare and life care businesses are working on taking up the challenge to enter new areas that create health support and joy for people through the five senses. During the nine months ended December 31, 2024, we made efforts to expand the healthcare and life care businesses. For Femtech-related products, we strove to increase their recognition through trade show exhibitions and launched offerings of new products. Additionally, we began producing improved Japanese lawn grass “Naruoturf®\*” as a way to enter the green infrastructure business. In the veterinary medical care business, we introduced various initiatives, including the launch of new products under the UniOne brand, which is aimed at general consumers.

\* “Naruoturf®” is a registered trademark.

As a result of these efforts, the Group's consolidated business results for the nine months ended December 31, 2024 were as follows.

Net sales increased by 4.7% year on year to ¥91,509 million due to expanded sales in daily disposable contact lenses in Japan and monthly replacement contact lenses in Europe, on top of the effects of the full-scale price revision in Japan. Operating profit increased by 13.8% year on year to ¥8,569 million as we ensured proper use of selling, general and administrative expenses, despite an increase in investment expenses for preparation of new plant operations, reinforcement of new product development, and human resources reinforcement by raising wages for employees and increasing our workforce, as well as expenses associated with the operation of the Global Logistics Center. Ordinary profit increased by 12.8% year on year to ¥8,198 million due mainly to an increase in interest expenses.

For extraordinary income and losses, extraordinary losses of ¥289 million were recorded mainly as a result of the recording of expenses associated with business restructuring at subsidiaries in Europe. As a result of the above factors, profit attributable to owners of parent increased by 11.8% year on year to ¥5,115 million.

Business results by segment are as follows.

#### 1) Vision Care Business

Sales of the Vision Care Business were ¥84,556 million, an increase of 5.5% year on year. Segment profit was ¥13,687 million, an increase of 12.3% year on year. The details are as follows.

Sales of the Vision Care Business increased by ¥4,429 million year on year. Sales of daily disposable contact lenses increased by ¥1,827 million, due to the effects of price revisions, an increase in the number of MELS Plan members for daily disposable contact lenses and increased sales volume through retail channels in Japan. Sales of orthokeratology-related products decreased by ¥37 million due to economic stagnation, the deteriorating competitive environment, and the spread of alternative products in China, although we were able to capture the strong demand for orthokeratology lenses in Japan, Singapore, Korea, and elsewhere. Other contact lens-related sales increased due mainly to the effects of price revisions within the MELS Plan and expanded sales in monthly replacement contact lenses in Europe.

Segment profit increased by ¥1,498 million year on year as we ensured proper use of selling, general and administrative expenses, despite an increase in investment expenses for preparation of new plant operations, reinforcement of new product development, and human resources reinforcement by raising wages for employees and increasing our workforce, as well as expenses associated with the operation of the Global Logistics Center.

#### 2) Other

Sales of Other businesses decreased by 4.4% year on year to ¥6,953 million, mainly due to a decrease in the food business sales in China as a result of the discharge of ALPS treated water, despite an increase in export sales in countries other than China and the effects of price revisions in Japan. Segment loss was ¥672 million, compared with a segment loss of ¥595 million for the same period of the previous year.

### (2) Financial Position

#### (Assets)

Total assets at the end of the third quarter of the fiscal year under review were ¥210,873 million, having increased by ¥31,061 million from the end of the previous fiscal year. Current assets increased by ¥20,634 million to ¥106,406 million, as cash and deposits increased due mainly to the issuance of bonds and the execution of syndicated loans for the purpose of redeeming the Zero Coupon Convertible Bonds due 2025. Non-current assets increased by ¥10,427 million to ¥104,467 million primarily due to the capital investments related to the construction of a manufacturing facility for daily disposable contact lenses at Menicon Malaysia Sdn. Bhd.

#### (Liabilities and net assets)

Liabilities increased by ¥24,846 million from the end of the previous fiscal year to ¥122,853 million primarily due to the issuance of bonds and the execution of syndicated loans for the purpose of redeeming the Zero Coupon Convertible

Bonds due 2025. Net assets increased by ¥6,215 million from the end of the previous fiscal year to ¥88,020 million, mainly due to the recording of profit attributable to owners of parent and an increase in foreign currency translation adjustment related to overseas subsidiaries as a result of the depreciating yen. As a result, the equity ratio was 40.5%.

(3) Consolidated Business Results Forecast and Other Forward-looking Information

Business results for the nine months ended December 31, 2024 showed generally stable net sales and gross profit. This stability is attributed to the effects of revenue growth due to the full-scale price revision in Japan, as well as expanded sales of daily disposable contact lenses in Japan and monthly replacement contact lenses in Europe, while orthokeratology-related product sales are being affected by economic stagnation, the deteriorating competitive environment, and the spread of alternative products in China. Operating profit was generally steady relative to the consolidated business results forecast for the full year ending March 31, 2025, due to the effects of the price revision and the proper use of general, selling and administrative expenses in Japan, despite the investment expenses chiefly for human resources reinforcement and research and development.

During the fourth quarter of the fiscal year under review, operating profit is expected to be lower than in each quarter of the nine months ended December 31, 2024. This is primarily due to the continued impact of economic stagnation and other factors on orthokeratology-related product sales in China, the implementation of sales promotions for the demand season in Japan, increased R&D expenditures, and higher expenses related to the Malaysia Plant.

As such, the consolidated business results forecast for the full year ending March 31, 2025 is unchanged from the forecast announced on May 14, 2024.

## 2. Quarterly Consolidated Financial Statements and Notes

### (1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2024	As of December 31, 2024
<b>Assets</b>		
Current assets		
Cash and deposits	46,911	63,758
Notes and accounts receivable - trade	13,340	14,496
Merchandise and finished goods	13,571	14,973
Work in process	1,470	1,382
Raw materials and supplies	3,761	4,373
Other	6,851	7,576
Allowance for doubtful accounts	(135)	(154)
Total current assets	85,771	106,406
Non-current assets		
Property, plant and equipment		
Buildings and structures	32,753	38,666
Accumulated depreciation	(14,126)	(15,268)
Buildings and structures, net	18,626	23,398
Machinery, equipment and vehicles	33,296	28,341
Accumulated depreciation	(21,669)	(18,998)
Machinery, equipment and vehicles, net	11,626	9,342
Tools, furniture and fixtures	11,202	11,628
Accumulated depreciation	(9,399)	(9,738)
Tools, furniture and fixtures, net	1,803	1,890
Land	5,658	5,661
Leased assets	2,211	6,031
Accumulated depreciation	(954)	(1,228)
Leased assets, net	1,256	4,803
Right of use assets	7,846	8,257
Accumulated depreciation	(4,083)	(4,918)
Right of use assets, net	3,762	3,338
Construction in progress	32,727	35,423
Other	46	46
Accumulated depreciation	-	-
Other, net	46	46
Total property, plant and equipment	75,508	83,904
Intangible assets		
Goodwill	2,719	4,506
Patent right	268	201
Other	8,680	9,225
Total intangible assets	11,668	13,933
Investments and other assets		
Investment securities	720	748
Deferred tax assets	2,978	2,422
Other	3,666	3,973
Allowance for doubtful accounts	(501)	(513)
Total investments and other assets	6,863	6,630
Total non-current assets	94,040	104,467
Total assets	179,812	210,873

(Millions of yen)

	As of March 31, 2024	As of December 31, 2024
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable - trade	6,181	6,560
Short-term borrowings	169	125
Current portion of bonds payable	166	166
Current portion of convertible-bond-type bonds with share acquisition rights	22,971	22,997
Current portion of long-term borrowings	1,633	979
Lease liabilities	1,275	2,079
Accounts payable - other	7,338	5,954
Income taxes payable	1,265	921
Provision for bonuses	2,076	1,215
Provision for point card certificates	24	30
Provision for loss on guarantees	488	-
Other	6,460	7,068
<b>Total current liabilities</b>	<b>50,053</b>	<b>48,097</b>
Non-current liabilities		
Bonds payable	36,333	46,167
Long-term borrowings	4,251	19,272
Lease liabilities	3,995	6,369
Long-term accounts payable - other	1,194	521
Retirement benefit liability	645	701
Deferred tax liabilities	1,036	1,122
Asset retirement obligations	259	109
Other	237	492
<b>Total non-current liabilities</b>	<b>47,953</b>	<b>74,755</b>
<b>Total liabilities</b>	<b>98,007</b>	<b>122,853</b>
<b>Net assets</b>		
Shareholders' equity		
Share capital	5,521	5,535
Capital surplus	7,309	7,558
Retained earnings	60,763	63,973
Treasury shares	(344)	(984)
<b>Total shareholders' equity</b>	<b>73,250</b>	<b>76,082</b>
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	283	318
Deferred gains or losses on hedges	-	0
Foreign currency translation adjustment	5,812	9,096
<b>Total accumulated other comprehensive income</b>	<b>6,096</b>	<b>9,415</b>
Share acquisition rights	2,403	2,465
Non-controlling interests	55	57
<b>Total net assets</b>	<b>81,804</b>	<b>88,020</b>
<b>Total liabilities and net assets</b>	<b>179,812</b>	<b>210,873</b>



## (2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income (For the nine months ended December 31)

(Millions of yen)

	For the nine months ended December 31, 2023	For the nine months ended December 31, 2024
Net sales	87,401	91,509
Cost of sales	41,563	42,069
Gross profit	45,837	49,439
Selling, general and administrative expenses	38,308	40,870
Operating profit	7,529	8,569
Non-operating income		
Interest income	53	87
Dividend income	14	18
Foreign exchange gains	63	-
Subsidy income	33	28
Other	192	204
Total non-operating income	357	339
Non-operating expenses		
Interest expenses	425	481
Bond issuance costs	101	45
Share of loss of entities accounted for using equity method	15	9
Foreign exchange losses	-	43
Other	74	130
Total non-operating expenses	617	710
Ordinary profit	7,269	8,198
Extraordinary income		
Gain on sale of non-current assets	99	3
Total extraordinary income	99	3
Extraordinary losses		
Loss on sale of non-current assets	-	1
Loss on retirement of non-current assets	27	79
Restructuring costs	-	209
Other	0	-
Total extraordinary losses	27	289
Profit before income taxes	7,341	7,912
Income taxes - current	2,596	2,176
Income taxes - deferred	166	618
Total income taxes	2,763	2,795
Profit	4,578	5,117
Profit attributable to non-controlling interests	2	2
Profit attributable to owners of parent	4,576	5,115

Quarterly Consolidated Statements of Comprehensive Income (For the nine months ended December 31)

(Millions of yen)

	For the nine months ended December 31, 2023	For the nine months ended December 31, 2024
Profit	4,578	5,117
Other comprehensive income		
Valuation difference on available-for-sale securities	97	34
Deferred gains or losses on hedges	-	0
Foreign currency translation adjustment	2,145	3,283
Share of other comprehensive income of entities accounted for using equity method	1	0
Total other comprehensive income	2,244	3,318
Comprehensive income	6,823	8,435
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	6,820	8,433
Comprehensive income attributable to non-controlling interests	2	2

### (3) Notes to Quarterly Consolidated Financial Statements

#### (Going concern assumption)

Not applicable.

#### (Significant changes in amount of shareholders' equity)

During the nine months ended December 31, 2024, in line with the reintroduction of the Employee Stock Ownership Plan (Stock Benefit Trust) treasury shares increased by ¥640 million. As a result, treasury shares as of December 31, 2024 were ¥984 million

#### (Changes in accounting policies)

(Application of "Accounting Standards for Corporate Tax, Resident Tax, and Business Tax")

The "Accounting Standards for Corporate Tax, Resident Tax, and Business Tax." (ASBJ Statement No. 27 issued October 28, 2022; hereinafter, "2022 Revised Accounting Standards"), have been applied from the beginning of the first quarter of this fiscal year.

With regard to the amendments to the classification of corporate tax (taxation on other comprehensive income), we follow the transitional treatment set forth in the proviso of paragraph 20-3 of the 2022 Revised Accounting Standards and the transitional treatment set forth in the proviso of paragraph 65-2 (2) of the "Guidelines for the Implementation of Accounting Standards for Tax-Effect Accounting" (Corporate Accounting Standards Implementation Guideline No. 28, October 28, 2022.). There is no impact on our group quarterly consolidated financial statements.

(Additional information)

(Transaction to grant the Company's shares to employees, etc. through a trust)

We conducted transactions to grant the Company's shares to the Employee Shareholder Association through a trust with the purpose of enhancing employee benefits and providing incentives for improving the Group's corporate value.

1. Overview of Transaction

We reintroduced the Employee Stock Ownership Plan (Stock Benefit Trust; hereinafter, the "Plan") for the Employee Shareholder Association in June 2024. It is an employee incentive plan similar to the Stock Benefit Trust (Employee Shareholder Association Purchase-Type) introduced in September 2021.

The Plan is an employee benefit program designed mainly with reference to the Employee Stock Ownership Plan (ESOP), an employee compensation package widely used in the U.S. as part of an employee incentive plan, and the "Report on Company Stock Holding Schemes" released by the Ministry of Economy, Trade and Industry of Japan on November 17, 2008.

We will establish a trust in which members of the Shareholder Association who satisfy a certain set of requirements are beneficiaries, and the said trust will acquire the number of the Company's shares that the Shareholder Association is expected to acquire during the trust period within the predetermined share-acquisition period. Then, the trust will sell the Company's shares to the Shareholder Association on the same day every month. If the trust has generated profits due to a rise in share prices or otherwise at the time of expiration of the trust, cash will be distributed to employees who satisfy the beneficiary requirements. If, on the other hand, the trust incurred a loss on transfer due to a decline in share prices and a debt pertaining to trust assets remains, there will be no additional burden on the part of employees as we will pay off the outstanding loan balance en bloc to the bank pursuant to warranty provisions of the non-recourse loan agreement.

2. Residual Company's Shares Held in the Trust

The residual Company's shares held in the Trust are recorded at the book value in the trust (excluding incidental expenses) as treasury shares under net assets. The book value and number of shares of such treasury shares are ¥20 million and 4 thousand shares, respectively, for the previous fiscal year, and ¥984 million and 757 thousand shares, respectively, for the third quarter of the fiscal year under review.

3. Book Value of Borrowings Recorded Through the Application of Total Amount Method

¥527 million for the previous consolidated fiscal year, ¥993 million for the third quarter of the fiscal year under review

(Segment information)

For the nine months ended December 31, 2023

1. Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment		Others (Note)	Total
	Vision Care Business	Subtotal		
Net sales				
Net sales to external customers	80,126	80,126	7,274	87,401
Inter-segment net sales or transfers	—	—	—	—
Total	80,126	80,126	7,274	87,401
Segment profit (loss)	12,189	12,189	(595)	11,593

(Note) “Others” is a business segment not included in the reportable segment, including the healthcare and life care businesses.

2. Differences between the total amount of profit or loss of the reportable segment and the amount stated in the consolidated statement of income, and major breakdown of such differences (Reconciliation)

(Millions of yen)

Profit	Amount
Reportable segment total	12,189
“Others” loss	(595)
Corporate expenses (Note)	(4,064)
Operating profit stated in the consolidated statement of income	7,529

(Note) Corporate expenses are mainly general and administrative expenses not attributable to the reportable segment.

3. Information on impairment loss of non-current assets, goodwill, etc. for the reportable segment

(Significant impairment loss on non-current assets)

Not applicable.

(Significant change in amount of goodwill)

Not applicable.

(Significant gain on bargain purchase)

Not applicable.

For the nine months ended December 31, 2024

1. Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment		Others (Note)	Total
	Vision Care Business	Subtotal		
Net sales				
Net sales to external customers	84,556	84,556	6,952	91,509
Inter-segment net sales or transfers	—	—	0	0
Total	84,556	84,556	6,953	91,509
Segment profit (loss)	13,687	13,687	(672)	13,014

(Note) “Others” is a business segment not included in the reportable segment, including the healthcare and life care businesses.

2. Differences between the total amount of profit or loss of the reportable segment and the amount stated in the consolidated statement of income, and major breakdown of such differences (Reconciliation)

(Millions of yen)

Profit	Amount
Reportable segment total	13,687
“Others” loss	(672)
Corporate expenses (Note)	(4,445)
Operating profit stated in the consolidated statement of income	8,569

(Note) Corporate expenses are mainly general and administrative expenses not attributable to the reportable segment.

3. Information on impairment loss of non-current assets, goodwill, etc. for the reportable segment

(Significant impairment loss on non-current assets)

Not applicable.

(Significant change in amount of goodwill)

Not applicable.

(Significant gain on bargain purchase)

Not applicable.

(Notes on consolidated statements of cash flows)

Quarterly consolidated statements of cash flows for the nine months ended December 31, 2024 have not been prepared. Depreciation (including amortization pertaining to intangible assets excluding goodwill) and amortization of goodwill pertaining to the nine months ended December 31, 2024 are as follows.

(Millions of yen)

	For the nine months ended December 31, 2023	For the nine months ended December 31, 2024
Depreciation	5,539	5,684
Amortization of goodwill	297	400